Successes and challenges in phenotype-based lead discovery for prion diseases

Journal of Medicinal Chemistry

Volumn 57, Issue 16, 2014, Pages 6919-6929

  Ghaemmaghami, Sina ^a   Russo, Miranda ^a   Renslo, Adam R ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2-AMINOTHIAZOLE; THIAZOLE DERIVATIVE;

ANIMAL; BRAIN; CHEMISTRY; CREUTZFELDT JAKOB DISEASE; DISEASE MODEL; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; METABOLISM; MOUSE; PRECLINICAL STUDY; PRION DISEASES; PROCEDURES; STRUCTURE ACTIVITY RELATION;

ANIMALS; BRAIN; CREUTZFELDT-JAKOB SYNDROME; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; PRION DISEASES; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 84906875759     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5001425     Document Type: Review

References (58)

1. Colby, D. W.; Prusiner, S. B. Prions Cold Spring Harbor Perspect Biol. 2011, 3, a006833
2. Prusiner, S. B. Novel proteinaceous infectious particles cause scrapie Science 1982, 216, 136-144
3. Prusiner, S. B. Shattuck lecture-neurodegenerative diseases and prions N. Engl. J. Med. 2001, 344, 1516-1526
4. Brown, P.; Cathala, F.; Castaigne, P.; Gajdusek, D. C. Creutzfeldt-Jakob disease: clinical analysis of a consecutive series of 230 neuropathologically verified cases Ann. Neurol. 1986, 20, 597-602
5. Roos, R.; Gajdusek, D. C.; Gibbs, C. J., Jr. The clinical characteristics of transmissible Creutzfeldt-Jakob disease Brain 1973, 96, 1-20
6. Collinge, J. Prion diseases of humans and animals: their causes and molecular basis Annu. Rev. Neurosci. 2001, 24, 519-550
7. Weissmann, C. The state of the prion Nat. Rev. Microbiol. 2004, 2, 861-871
8. Zahn, R.; Liu, A.; Luhrs, T.; Riek, R.; von Schroetter, C.; Lopez Garcia, F.; Billeter, M.; Calzolai, L.; Wider, G.; Wuthrich, K. NMR solution structure of the human prion protein Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 145-150
9. Sonati, T.; Reimann, R. R.; Falsig, J.; Baral, P. K.; O'Connor, T.; Hornemann, S.; Yaganoglu, S.; Li, B.; Herrmann, U. S.; Wieland, B.; Swayampakula, M.; Rahman, M. H.; Das, D.; Kav, N.; Riek, R.; Liberski, P. P.; James, M. N.; Aguzzi, A. The toxicity of antiprion antibodies is mediated by the flexible tail of the prion protein Nature 2013, 501, 102-106
10. Baral, P. K.; Swayampakula, M.; Rout, M. K.; Kav, N. N.; Spyracopoulos, L.; Aguzzi, A.; James, M. N. Structural basis of prion inhibition by phenothiazine compounds Structure 2014, 22, 291-303
11. Wasmer, C.; Lange, A.; Van Melckebeke, H.; Siemer, A. B.; Riek, R.; Meier, B. H. Amyloid fibrils of the het-s(218-289) prion form a beta solenoid with a triangular hydrophobic core Science 2008, 319, 1523-1526
12. Bueler, H.; Fischer, M.; Lang, Y.; Bluethmann, H.; Lipp, H. P.; DeArmond, S. J.; Prusiner, S. B.; Aguet, M.; Weissmann, C. Normal development and behaviour of mice lacking the neuronal cell-surface prp protein Nature 1992, 356, 577-582
13. Richt, J. A.; Kasinathan, P.; Hamir, A. N.; Castilla, J.; Sathiyaseelan, T.; Vargas, F.; Sathiyaseelan, J.; Wu, H.; Matsushita, H.; Koster, J.; Kato, S.; Ishida, I.; Soto, C.; Robl, J. M.; Kuroiwa, Y. Production of cattle lacking prion protein Nat. Biotechnol. 2007, 25, 132-138
14. Yu, G.; Chen, J.; Xu, Y.; Zhu, C.; Yu, H.; Liu, S.; Sha, H.; Chen, J.; Xu, X.; Wu, Y.; Zhang, A.; Ma, J.; Cheng, G. Generation of goats lacking prion protein Mol. Reprod. Dev. 2009, 76, 3
15. Aguzzi, A.; Falsig, J. Prion propagation, toxicity and degradation Nat. Neurosci. 2012, 15, 936-939
16. Hewitt, P. E.; Llewelyn, C. A.; Mackenzie, J.; Will, R. G. Creutzfeldt-Jakob disease and blood transfusion: results of the UK transfusion medicine epidemiological review study Vox Sang. 2006, 91, 221-230
17. Otto, M.; Cepek, L.; Ratzka, P.; Doehlinger, S.; Boekhoff, I.; Wiltfang, J.; Irle, E.; Pergande, G.; Ellers-Lenz, B.; Windl, O.; Kretzschmar, H. A.; Poser, S.; Prange, H. Efficacy of flupirtine on cognitive function in patients with CJD: a double-blind study Neurology 2004, 62, 714-718
18. Geschwind, M. D.; Kuo, A. L.; Wong, K. S.; Haman, A.; Devereux, G.; Raudabaugh, B. J.; Johnson, D. Y.; Torres-Chae, C. C.; Finley, R.; Garcia, P.; Thai, J. N.; Cheng, H. Q.; Neuhaus, J. M.; Forner, S. A.; Duncan, J. L.; Possin, K. L.; Dearmond, S. J.; Prusiner, S. B.; Miller, B. L. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease Neurology 2013, 81, 2015-2023
19. Haik, S.; Marcon, G.; Mallet, A.; Tettamanti, M.; Welaratne, A.; Giaccone, G.; Azimi, S.; Pietrini, V.; Fabreguettes, J. R.; Imperiale, D.; Cesaro, P.; Buffa, C.; Aucan, C.; Lucca, U.; Peckeu, L.; Suardi, S.; Tranchant, C.; Zerr, I.; Houillier, C.; Redaelli, V.; Vespignani, H.; Campanella, A.; Sellal, F.; Krasnianski, A.; Seilhean, D.; Heinemann, U.; Sedel, F.; Canovi, M.; Gobbi, M.; Di Fede, G.; Laplanche, J. L.; Pocchiari, M.; Salmona, M.; Forloni, G.; Brandel, J. P.; Tagliavini, F. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial Lancet Neurol. 2014, 13, 150-158
20. Geissen, M.; Leidel, F.; Eiden, M.; Hirschberger, T.; Fast, C.; Bertsch, U.; Tavan, P.; Giese, A.; Kretzschmar, H.; Schatzl, H. M.; Groschup, M. H. From high-throughput cell culture screening to mouse model: identification of new inhibitor classes against prion disease ChemMedChem 2011, 6, 1928-1937
21. Vilette, D. Cell models of prion infection Vet. Res. 2008, 39, 10
22. Safar, J. G.; Geschwind, M. D.; Deering, C.; Didorenko, S.; Sattavat, M.; Sanchez, H.; Serban, A.; Vey, M.; Baron, H.; Giles, K.; Miller, B. L.; Dearmond, S. J.; Prusiner, S. B. Diagnosis of human prion disease Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 3501-3506
23. Brandner, S.; Klein, M. A.; Frigg, R.; Pekarik, V.; Parizek, P.; Raeber, A.; Glatzel, M.; Schwarz, P.; Rulicke, T.; Weissmann, C.; Aguzzi, A. Neuroinvasion of prions: insights from mouse models Exp. Physiol. 2000, 85, 705-712
24. Tamguney, G.; Francis, K. P.; Giles, K.; Lemus, A.; DeArmond, S. J.; Prusiner, S. B. Measuring prions by bioluminescence imaging Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 15002-15006
25. Kuwata, K.; Nishida, N.; Matsumoto, T.; Kamatari, Y. O.; Hosokawa-Muto, J.; Kodama, K.; Nakamura, H. K.; Kimura, K.; Kawasaki, M.; Takakura, Y.; Shirabe, S.; Takata, J.; Kataoka, Y.; Katamine, S. Hot spots in prion protein for pathogenic conversion Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 11921-11926
26. Trevitt, C. R.; Collinge, J. A systematic review of prion therapeutics in experimental models Brain 2006, 129, 2241-2265
27. Sim, V. L. Prion disease: chemotherapeutic strategies Infect. Disord.: Drug Targets 2012, 12, 144-160
28. Kamatari, Y. O.; Hayano, Y.; Yamaguchi, K.; Hosokawa-Muto, J.; Kuwata, K. Characterizing antiprion compounds based on their binding properties to prion proteins: implications as medical chaperones Protein Sci. 2013, 22, 22-34
29. Ghaemmaghami, S.; Ahn, M.; Lessard, P.; Giles, K.; Legname, G.; DeArmond, S. J.; Prusiner, S. B. Continuous quinacrine treatment results in the formation of drug-resistant prions PLoS Pathog. 2009, 5, e1000673
30. Forloni, G.; Iussich, S.; Awan, T.; Colombo, L.; Angeretti, N.; Girola, L.; Bertani, I.; Poli, G.; Caramelli, M.; Grazia Bruzzone, M.; Farina, L.; Limido, L.; Rossi, G.; Giaccone, G.; Ironside, J. W.; Bugiani, O.; Salmona, M.; Tagliavini, F. Tetracyclines affect prion infectivity Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 10849-10854
31. Teruya, K.; Kawagoe, K.; Kimura, T.; Chen, C. J.; Sakasegawa, Y.; Doh-ura, K. Amyloidophilic compounds for prion diseases Infect. Disord.: Drug Targets 2009, 9, 15-22
32. Moreno, J. A.; Halliday, M.; Molloy, C.; Radford, H.; Verity, N.; Axten, J. M.; Ortori, C. A.; Willis, A. E.; Fischer, P. M.; Barrett, D. A.; Mallucci, G. R. Oral treatment targeting the unfolded protein response prevents neurodegeneration and clinical disease in prion-infected mice Sci. Transl. Med. 2013, 5, 206ra138
33. Axten, J. M.; Medina, J. R.; Feng, Y.; Shu, A.; Romeril, S. P.; Grant, S. W.; Li, W. H.; Heerding, D. A.; Minthorn, E.; Mencken, T.; Atkins, C.; Liu, Q.; Rabindran, S.; Kumar, R.; Hong, X.; Goetz, A.; Stanley, T.; Taylor, J. D.; Sigethy, S. D.; Tomberlin, G. H.; Hassell, A. M.; Kahler, K. M.; Shewchuk, L. M.; Gampe, R. T. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}- 2,3-dihydro-1 H -indol-5-yl)-7 H -pyrrolo[2,3- d ]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) J. Med. Chem. 2012, 55, 7193-7207
34. Wagner, J.; Ryazanov, S.; Leonov, A.; Levin, J.; Shi, S.; Schmidt, F.; Prix, C.; Pan-Montojo, F.; Bertsch, U.; Mitteregger-Kretzschmar, G.; Geissen, M.; Eiden, M.; Leidel, F.; Hirschberger, T.; Deeg, A.; Krauth, J.; Zinth, W.; Tavan, P.; Pilger, J.; Zweckstetter, M.; Frank, T.; Bähr, M.; Weishaupt, J.; Uhr, M.; Urlaub, H.; Teichmann, U.; Samwer, M.; Bötzel, K.; Groschup, M.; Kretzschmar, H.; Griesinger, C.; Giese, A. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease Acta Neuropathol. 2013, 125, 795-813
35. Berry, D. B.; Lu, D.; Geva, M.; Watts, J. C.; Bhardwaj, S.; Oehler, A.; Renslo, A. R.; DeArmond, S. J.; Prusiner, S. B.; Giles, K. Drug resistance confounding prion therapeutics Proc. Natl. Acad. Sci. U.S.A. 2013, 110, E4160-4169
36. Kocisko, D. A.; Baron, G. S.; Rubenstein, R.; Chen, J.; Kuizon, S.; Caughey, B. New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products J. Virol. 2003, 77, 10288-10294
37. Bertsch, U.; Winklhofer, K. F.; Hirschberger, T.; Bieschke, J.; Weber, P.; Hartl, F. U.; Tavan, P.; Tatzelt, J.; Kretzschmar, H. A.; Giese, A. Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets J. Virol. 2005, 79, 7785-7791
38. Ghaemmaghami, S.; May, B. C.; Renslo, A. R.; Prusiner, S. B. Discovery of 2-aminothiazoles as potent antiprion compounds J. Virol. 2010, 84, 3408-3412
39. Kalgutkar, A. S.; Driscoll, J.; Zhao, S. X.; Walker, G. S.; Shepard, R. M.; Soglia, J. R.; Atherton, J.; Yu, L.; Mutlib, A. E.; Munchhof, M. J.; Reiter, L. A.; Jones, C. S.; Doty, J. L.; Trevena, K. A.; Shaffer, C. L.; Ripp, S. L. A rational chemical intervention strategy to circumvent bioactivation liabilities associated with a nonpeptidyl thrombopoietin receptor agonist containing a 2-amino-4-arylthiazole motif Chem. Res. Toxicol. 2007, 20, 1954-1965
40. Borzilleri, R. M.; Bhide, R. S.; Barrish, J. C.; D'Arienzo, C. J.; Derbin, G. M.; Fargnoli, J.; Hunt, J. T.; Jeyaseelan, R., Sr.; Kamath, A.; Kukral, D. W.; Marathe, P.; Mortillo, S.; Qian, L.; Tokarski, J. S.; Wautlet, B. S.; Zheng, X.; Lombardo, L. J. Discovery and evaluation of N -cyclopropyl-2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)amino) benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2 J. Med. Chem. 2006, 49, 3766-3769
41. Das, J.; Chen, P.; Norris, D.; Padmanabha, R.; Lin, J.; Moquin, R. V.; Shen, Z.; Cook, L. S.; Doweyko, A. M.; Pitt, S.; Pang, S.; Shen, D. R.; Fang, Q.; de Fex, H. F.; McIntyre, K. W.; Shuster, D. J.; Gillooly, K. M.; Behnia, K.; Schieven, G. L.; Wityak, J.; Barrish, J. C. 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N -(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2- methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor J. Med. Chem. 2006, 49, 6819-6832
42. Press, N. J.; Taylor, R. J.; Fullerton, J. D.; Tranter, P.; McCarthy, C.; Keller, T. H.; Brown, L.; Cheung, R.; Christie, J.; Haberthuer, S.; Hatto, J. D.; Keenan, M.; Mercer, M. K.; Press, N. E.; Sahri, H.; Tuffnell, A. R.; Tweed, M.; Fozard, J. R. A new orally bioavailable dual adenosine a2b/a3 receptor antagonist with therapeutic potential Bioorg. Med. Chem. Lett. 2005, 15, 3081-3085
43. van Muijlwijk-Koezen, J. E.; Timmerman, H.; Vollinga, R. C.; Frijtag von Drabbe Kunzel, J.; de Groote, M.; Visser, S.; Ijzerman, A. P. Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists J. Med. Chem. 2001, 44, 749-762
44. Turcotte, S.; Chan, D. A.; Sutphin, P. D.; Hay, M. P.; Denny, W. A.; Giaccia, A. J. A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy Cancer Cell 2008, 14, 90-102
45. Lubbers, T.; Flohr, A.; Jolidon, S.; David-Pierson, P.; Jacobsen, H.; Ozmen, L.; Baumann, K. Aminothiazoles as gamma-secretase modulators Bioorg. Med. Chem. Lett. 2011, 21, 6554-6558
46. Kounnas, M. Z.; Danks, A. M.; Cheng, S.; Tyree, C.; Ackerman, E.; Zhang, X.; Ahn, K.; Nguyen, P.; Comer, D.; Mao, L.; Yu, C.; Pleynet, D.; Digregorio, P. J.; Velicelebi, G.; Stauderman, K. A.; Comer, W. T.; Mobley, W. C.; Li, Y. M.; Sisodia, S. S.; Tanzi, R. E.; Wagner, S. L. Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease Neuron 2010, 67, 769-780
47. Gallardo-Godoy, A.; Gever, J.; Fife, K. L.; Silber, B. M.; Prusiner, S. B.; Renslo, A. R. 2-Aminothiazoles as therapeutic leads for prion diseases J. Med. Chem. 2011, 54, 1010-1021
48. Li, Z.; Silber, B. M.; Rao, S.; Gever, J. R.; Bryant, C.; Gallardo-Godoy, A.; Dolghih, E.; Widjaja, K.; Elepano, M.; Jacobson, M. P.; Prusiner, S. B.; Renslo, A. R. 2-Aminothiazoles with improved pharmacotherapeutic properties for treatment of prion disease ChemMedChem 2013, 8, 847-857
49. Ghaemmaghami, S.; Ullman, J.; Ahn, M.; St Martin, S.; Prusiner, S. B. Chemical induction of misfolded prion protein conformers in cell culture J. Biol. Chem. 2010, 285, 10415-10423
50. Silber, B. M.; Rao, S.; Fife, K. L.; Gallardo-Godoy, A.; Renslo, A. R.; Dalvie, D. K.; Giles, K.; Freyman, Y.; Elepano, M.; Gever, J. R.; Li, Z.; Jacobson, M. P.; Huang, Y.; Benet, L. Z.; Prusiner, S. B. Pharmacokinetics and metabolism of 2-aminothiazoles with antiprion activity in mice Pharm. Res. 2013, 30, 932-950
51. Hitchcock, S. A.; Pennington, L. D. Structure-brain exposure relationships J. Med. Chem. 2006, 49, 7559-7583
52. Lu, D.; Giles, K.; Li, Z.; Rao, S.; Dolghih, E.; Gever, J. R.; Geva, M.; Elepano, M. L.; Oehler, A.; Bryant, C.; Renslo, A. R.; Jacobson, M. P.; Dearmond, S. J.; Silber, B. M.; Prusiner, S. B. Biaryl amides and hydrazones as therapeutics for prion disease in transgenic mice J. Pharmacol. Exp. Ther. 2013, 347, 325-338
53. Li, J.; Browning, S.; Mahal, S. P.; Oelschlegel, A. M.; Weissmann, C. Darwinian evolution of prions in cell culture Science 2010, 327, 869-872
54. Miller-Vedam, L.; Ghaemmaghami, S. Strain specificity and drug resistance in anti-prion therapy Curr. Top. Med. Chem. 2013, 13, 2397-2406
55. Prusiner, S. B. Cell biology. A unifying role for prions in neurodegenerative diseases Science 2012, 336, 1511-1513
56. Jucker, M.; Walker, L. C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases Nature 2013, 501, 45-51
57. Guo, J. L.; Covell, D. J.; Daniels, J. P.; Iba, M.; Stieber, A.; Zhang, B.; Riddle, D. M.; Kwong, L. K.; Xu, Y.; Trojanowski, J. Q.; Lee, V. M. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons Cell 2013, 154, 103-117
58. Clavaguera, F.; Akatsu, H.; Fraser, G.; Crowther, R. A.; Frank, S.; Hench, J.; Probst, A.; Winkler, D. T.; Reichwald, J.; Staufenbiel, M.; Ghetti, B.; Goedert, M.; Tolnay, M. Brain homogenates from human tauopathies induce tau inclusions in mouse brain Proc. Natl. Acad. Sci. U.S.A. 2013, 110, 9535-9540